Special Issue "Targeting Innate Immunity Cells in Cancer"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 January 2020

Special Issue Editor

Guest Editor
Prof. Rafael Solana

Maimonides Biomedicine Institute of Cordoba (IMIBIC), Reina Sofia, University Hospital-University of Cordoba, Cordoba, Spain
Website | E-Mail
Interests: immunosenescence; NK cells; T and NK cell-based immunotherapy; cytomegalovirus; leukemia

Special Issue Information

Dear Colleagues,

Advances in the better understanding of the relationship between the immune system and cancer have enabled the development of a broad arsenal of strategies aiming to target different aspects of the immune response for cancer treatment. Natural killer (NK) cells and other innate immunity cells are involved in the defense against tumors and viral infections. Their phenotype and function are strongly affected in patients with cancer. The deeper analysis of these cell alterations not only in cancer but also in other clinical conditions such as viral infection, chronic inflammation, autoimmunity, or ageing will contribute to the design of new therapeutic strategies aiming to modulate NK cell effector functions and to restore their antitumor functionality. In addition, therapeutic antibodies blocking checkpoints in innate immune cells, bispecific linker proteins, or NK cell-based adoptive cellular immunotherapy, including CAR-NK cells, can constitute new weapons to fight cancer. Thus, the aim of this Special Issue is to highlight recent studies on the interaction of NK and other innate immune cells with cancer cells and the potential to modulate innate immunity in cancer therapy.

Prof. Rafael Solana
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview Tumor-Associated Neutrophils in Cancer: Going Pro
Cancers 2019, 11(4), 564; https://doi.org/10.3390/cancers11040564
Received: 15 March 2019 / Revised: 9 April 2019 / Accepted: 17 April 2019 / Published: 19 April 2019
PDF Full-text (1254 KB) | HTML Full-text | XML Full-text
Abstract
The progression of cancer is not only about the tumor cell itself, but also about other involved players including cancer cell recruited immune cells, their released pro-inflammatory factors, and the extracellular matrix. These players constitute the tumor microenvironment and play vital roles in [...] Read more.
The progression of cancer is not only about the tumor cell itself, but also about other involved players including cancer cell recruited immune cells, their released pro-inflammatory factors, and the extracellular matrix. These players constitute the tumor microenvironment and play vital roles in the cancer progression. Neutrophils—the most abundant white blood cells in the circulation system—constitute a significant part of the tumor microenvironment. Neutrophils play major roles linking inflammation and cancer and are actively involved in progression and metastasis. Additionally, recent data suggest that neutrophils could be considered one of the emerging targets for multiple cancer types. This review summarizes the most recent updates regarding neutrophil recruitments and functions in the tumor microenvironment as well as potential development of neutrophils-targeted putative therapeutic strategies. Full article
(This article belongs to the Special Issue Targeting Innate Immunity Cells in Cancer)
Figures

Figure 1

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top